Global News

Great Gift moves to Innovation Quarter

Tuesday, September 19, 2017

Jennifer Byrne is the founder of Greater Gift, a nonprofit organization that facilitates the donation of vaccines in honor of clinical research participants. Seeing students walk by every day on the way to class, she envisions the impact that these future doctors, physician assistants and certified nurses can have on their patients—not only through patient care, but also through promoting clinical research.

[Read More]

Catalent to acquire Cook Pharmica for $950M

Tuesday, September 19, 2017

Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has reached an agreement to acquire Bloomington, Indiana-based Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services. The purchase price is $950 million, with $750 million to be paid at closing and the balance to be paid in equal installments, without interest, on each of the next four anniversaries of the closing. The acquisition will strengthen Catalent’s position as a leader in the rapidly growing area of biologics development and analytical services, manufacturing, and finished product supply.

[Read More]

Aequus, Ehave collaborate on bioinformatics platform

Monday, September 18, 2017

Aequus Pharmaceuticals, a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, a healthcare bioinformatics company whose platform efficiently captures, integrates and delivers high-quality clinical data and treatment tools, have entered into a collaboration whereby Aequus will gain access to Ehave’s bioinformatics platform for use in Aequus’ anticipated clinical trials for its portfolio products, with an initial focus in neurology.

[Read More]

BioTime awarded $1.5M grant from the NIH

Monday, September 18, 2017

BioTime, a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, has been awarded a grant of up to $1.56 million from the Small Business Innovation Research program of the NIH. The grant provides funding to further develop BioTime’s innovative, next generation vision restoration program for more advanced retinal diseases and injuries, which severely impact the quality of life for millions of people with no treatment option. This initiative aims at improving vision in people affected by blindness, whether caused by retinal injuries, age-related macular degeneration, retinitis pigmentosa or other causes.

[Read More]

Cell Medica appoints Luis Borges as CSO to accelerate R&D for CAR and TCR Programs

Monday, September 18, 2017

Cell Medica, a provider of cell-based immunotherapies for the treatment of cancer, announced the appointment of Luis Borges, Ph.D., as Chief Scientific Officer. Luis will spearhead the Company’s global research group, including teams in London, Zurich and Houston. Luis brings extensive knowledge of cancer immunotherapy from twenty years of experience in the field, including senior positions at Five Prime Therapeutics and Amgen, where he played a senior role in the discovery and development of several blockbuster drugs and therapeutic candidate molecules.

[Read More]